v3.25.4
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Revenue $ 5,213 $ 5,824
Revenue, Product and Service [Extensible Enumeration] Grant [Member] Grant [Member]
Operating expenses:    
Research and development $ 8,379 $ 10,580
General and administrative 12,132 9,939
Total operating expenses 20,511 20,519
Operating loss (15,298) (14,695)
Other income (expense):    
Financing expense (3,061) (3,545)
Change in fair value of derivative instruments (2,631) 5,654
Warrant issuance costs (964) (486)
Interest income 116 273
Interest expense (548) (179)
Total other income (expense) (7,088) 1,717
Net loss $ (22,386) $ (12,978)
Net loss per share of common stock - basic $ (0.29) $ (1.95)
Net loss per share of common stock - diluted $ (0.29) $ (2.34)
Weighted average number of shares of common stock outstanding - basic 77,804,612 6,640,251
Weighted average number of shares of common stock outstanding - diluted 77,804,612 7,700,774